Research Alliance Corp III — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Research Alliance Corp III (SPAC) agreed to acquire OHB Pediatrics Ltd., a clinical-stage biopharmaceutical company developing rugonersen (antisense oligonucleotide for Angelman syndrome). Base equity value is $160M; closing consideration is $160M ÷ $10 = 16M SPAC shares (before dilution adjustments). Oak Hill Bio Holdings Ltd. holds 65.72% of OHB pre-close. Sponsor will provide $45M interim financing via SAFEs; PIPE investors will fund additional capital. Transaction includes domestication of SPAC from Cayman to Delaware and sponsor share conversion.
Why this rating
SPAC has ~$733K assets; $160M deal is massive relative to SPAC size, but SPACs are shells designed for acquisitions. Standard merger terms, representations, and mechanics. No material adverse facts disclosed. Routine for SPAC context; routine for biotech M&A.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.